PURPOSE: A common genetic variant (rs3812718) in a splice donor consensus sequence within the neuronal sodium channel gene SCN1A (encoding Na(V) 1.1) modulates the proportion of transcripts incorporating either the canonical (5A) or alternative (5N) exon 5. A pharmacogenetic association has been reported whereby increased expression of exon 5N containing Na(V) 1.1 transcripts correlated with lower required doses of phenytoin in epileptics. We tested the hypothesis that SCN1A alternative splicing affects the pharmacology of Na(V) 1.1 channels. METHODS: To directly examine biophysical and pharmacologic differences between the exon 5 splice variants, we performed whole-cell patch clamp recording of tsA201 cells transiently coexpressing either Na(V) 1.1-5A or Na(V) 1.1-5N with the β1 and β2 accessory subunits. We examined tonic inhibition and use-dependent inhibition of Na(V) 1.1 splice isoforms by phenytoin, carbamazepine, and lamotrigine. We also examined the effects of phenytoin and lamotrigine on channel biophysical properties and determined concentration-response relationships for both splice variants. KEY FINDINGS: We observed no significant differences in voltage dependence of activation, steady-state inactivation, and recovery from inactivation between splice variants. However, Na(V) 1.1-5N channels exhibited enhanced tonic block by phenytoin and lamotrigine compared to Na(V) 1.1-5A. In addition, Na(V) 1.1-5N exhibited enhanced use-dependent block by phenytoin and lamotrigine across a range of stimulation frequencies and concentrations. Phenytoin and lamotrigine induced shifts in steady-state inactivation and recovery from fast inactivation for both splice isoforms. No splice isoform differences were observed for channel inhibition by carbamazepine. SIGNIFICANCE: These results suggest Na(V) 1.1 channels containing exon 5N are more sensitive to the commonly used antiepileptic drugs phenytoin and lamotrigine. Wiley Periodicals, Inc.
PURPOSE: A common genetic variant (rs3812718) in a splice donor consensus sequence within the neuronal sodium channel gene SCN1A (encoding Na(V) 1.1) modulates the proportion of transcripts incorporating either the canonical (5A) or alternative (5N) exon 5. A pharmacogenetic association has been reported whereby increased expression of exon 5N containing Na(V) 1.1 transcripts correlated with lower required doses of phenytoin in epileptics. We tested the hypothesis that SCN1A alternative splicing affects the pharmacology of Na(V) 1.1 channels. METHODS: To directly examine biophysical and pharmacologic differences between the exon 5 splice variants, we performed whole-cell patch clamp recording of tsA201 cells transiently coexpressing either Na(V) 1.1-5A or Na(V) 1.1-5N with the β1 and β2 accessory subunits. We examined tonic inhibition and use-dependent inhibition of Na(V) 1.1 splice isoforms by phenytoin, carbamazepine, and lamotrigine. We also examined the effects of phenytoin and lamotrigine on channel biophysical properties and determined concentration-response relationships for both splice variants. KEY FINDINGS: We observed no significant differences in voltage dependence of activation, steady-state inactivation, and recovery from inactivation between splice variants. However, Na(V) 1.1-5N channels exhibited enhanced tonic block by phenytoin and lamotrigine compared to Na(V) 1.1-5A. In addition, Na(V) 1.1-5N exhibited enhanced use-dependent block by phenytoin and lamotrigine across a range of stimulation frequencies and concentrations. Phenytoin and lamotrigine induced shifts in steady-state inactivation and recovery from fast inactivation for both splice isoforms. No splice isoform differences were observed for channel inhibition by carbamazepine. SIGNIFICANCE: These results suggest Na(V) 1.1 channels containing exon 5N are more sensitive to the commonly used antiepileptic drugs phenytoin and lamotrigine. Wiley Periodicals, Inc.
Authors: Sarah K Tate; Rinki Singh; Chin-Chuan Hung; John Jen Tai; Chantal Depondt; Gianpiero L Cavalleri; Sanjay M Sisodiya; David B Goldstein; Horng-Huei Liou Journal: Pharmacogenet Genomics Date: 2006-10 Impact factor: 2.089
Authors: Fritz Zimprich; Elisabeth Stogmann; Silvia Bonelli; Christoph Baumgartner; Jakob C Mueller; Thomas Meitinger; Alexander Zimprich; Tim M Strom Journal: Epilepsia Date: 2008-06 Impact factor: 5.864
Authors: Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein Journal: Proc Natl Acad Sci U S A Date: 2005-04-01 Impact factor: 11.205
Authors: Erin L Heinzen; Woohyun Yoon; Sarah K Tate; Arjune Sen; Nicholas W Wood; Sanjay M Sisodiya; David B Goldstein Journal: Am J Hum Genet Date: 2007-04-03 Impact factor: 11.025
Authors: Larry Baum; Batoul Sadat Haerian; Ho-Keung Ng; Virginia C N Wong; Ping Wing Ng; Colin H T Lui; Ngai Chuen Sin; Chunbo Zhang; Brian Tomlinson; Gary Wing-Kin Wong; Hui Jan Tan; Azman Ali Raymond; Zahurin Mohamed; Patrick Kwan Journal: Hum Genet Date: 2013-12-13 Impact factor: 4.132
Authors: Lyndsey L Anderson; Christopher H Thompson; Nicole A Hawkins; Ravi D Nath; Adam A Petersohn; Sridharan Rajamani; William S Bush; Wayne N Frankel; Carlos G Vanoye; Jennifer A Kearney; Alfred L George Journal: Epilepsia Date: 2014-05-23 Impact factor: 5.864
Authors: Christopher H Thompson; Nicole A Hawkins; Jennifer A Kearney; Alfred L George Journal: Proc Natl Acad Sci U S A Date: 2017-01-30 Impact factor: 11.205
Authors: Tracy A Glauser; Katherine Holland; Valerie P O'Brien; Mehdi Keddache; Lisa J Martin; Peggy O Clark; Avital Cnaan; Dennis Dlugos; Deborah G Hirtz; Shlomo Shinnar; Gregory Grabowski Journal: Ann Neurol Date: 2017-03 Impact factor: 10.422
Authors: Caroline F Thorn; Michelle Whirl-Carrillo; J Steven Leeder; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2012-06 Impact factor: 2.089
Authors: Christopher H Thompson; J Christopher Porter; Kristopher M Kahlig; Melissa A Daniels; Alfred L George Journal: J Biol Chem Date: 2012-10-19 Impact factor: 5.157